glp-1 gen 5 The revolution: What UAB researchers are discovering about how these drugs work Not available to the following states The GLP-1 Revolution: From Diabetes
Description
Low Dose Semaglutide Modulates Myocardial and Hepatic Proteomics To further elucidate the molecular mechanisms underlying semaglutides beneficial effects, we performed a proteomic analysis of myocardial and hepatic tissues
Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides
Noetel M, Sanders T, Gallardo-Gmez D, Taylor P, Del Pozo Cruz B, van den Hoek D, et al
In 2025, Novo Nordisk submitted Orforglipron for regulatory review by the FDA, but it is not yet approved
Overweight and obesity significantly increase the risk of various gastrointestinal disorders [25], and they often co-occur with T2DM in patients
People with obesity often have lower GLP-1 sensitivity or insufficient hormone production, meaning their bodies do not receive these fullness signals effectively
